A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson’s disease
Frontiers in Pharmacology · 29.05.2026 · 17
DOI: 10.3389/fphar.2026.1817435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Sayaphat Suksai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, Faculty of Science, Srinakharinwirot University, Bangkok, Thailand. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Srinakharinwirot University, Chiang Mai University.
Abstract (Originalsprache)
Parkinson’s disease is associated with substantial inter-patient variability in motor response to levodopa therapy, making long-term dose selection and scheduling challenging. Computational modeling provides a systematic approach for investigating how pharmacokinetic and pharmacodynamic variability may influence treatment outcomes. This study presents a computational pharmacokinetic–pharmacodynamic framework for simulating and comparing individualized levodopa dosing strategies in Parkinson’s disease. The framework integrates multi-compartment drug disposition, effect-site dynamics, and a nonlinear exposure–response relationship, using parameter ranges derived from published clinical and modeling studies. A heterogeneous virtual cohort was generated to represent variability in absorption, clearance, distribution, and pharmacodynamic sensitivity, and simulation-based optimization was applied to evaluate the effects of dose size, dosing interval, and timing across representative patient scenarios. Simulations demonstrated how alternative dosing schedules influence effect-site exposure stability and predicted therapeutic response patterns under inter-patient variability. Sensitivity analysis further identified key parameters contributing most strongly to simulated exposure–response behavior. Rather than providing prescriptive clinical recommendations, the proposed framework serves as an in silico platform for comparing dosing regimens, evaluating scenario-specific strategies, and generating hypotheses for future data-driven validation. These findings highlight the potential of simulation-based PK–PD modeling to support individualized treatment exploration and future model-informed dosing research in Parkinson’s disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mathematics, Faculty of Science, Srinakharinwirot University, Bangkok, Thailand.
- Department of Mathematics, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand.
Förderung
- Srinakharinwirot University
- Chiang Mai University
Zitieren
APA
Suksai, S., Suantai, S., & Wandee, P. (2026). A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson’s disease. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1817435
Vancouver
Suksai S, Suantai S, Wandee P. A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson’s disease. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1817435
BibTeX
@article{Suksai2026,
author = {Suksai, Sayaphat and Suantai, Suthep and Wandee, Pawarit},
title = {A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson’s disease},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1817435}
}
EUVIMED